184 related articles for article (PubMed ID: 33619913)
1. Real world clinicopathologic observations of patients with metastatic solid tumors receiving immune checkpoint inhibitor therapy: Analysis from Kentucky Cancer Registry.
Jacob A; Wu J; Kolesar J; Durbin E; Mathew A; Arnold S; Chauhan A
Cancer Med; 2021 Mar; 10(6):2054-2062. PubMed ID: 33619913
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.
Goodman AM; Piccioni D; Kato S; Boichard A; Wang HY; Frampton G; Lippman SM; Connelly C; Fabrizio D; Miller V; Sicklick JK; Kurzrock R
JAMA Oncol; 2018 Sep; 4(9):1237-1244. PubMed ID: 29902298
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
[TBL] [Abstract][Full Text] [Related]
4. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors.
Chen Y; Li Y; Guan Y; Huang Y; Lin J; Chen L; Li J; Chen G; Pan LK; Xia X; Xu N; Chang L; Guo Z; Pan J; Yi X; Chen C
Mol Oncol; 2020 Sep; 14(9):2096-2110. PubMed ID: 32502294
[TBL] [Abstract][Full Text] [Related]
6. Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients.
Richard C; Fumet JD; Chevrier S; Derangère V; Ledys F; Lagrange A; Favier L; Coudert B; Arnould L; Truntzer C; Boidot R; Ghiringhelli F
Clin Cancer Res; 2019 Feb; 25(3):957-966. PubMed ID: 30154227
[TBL] [Abstract][Full Text] [Related]
7. Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations.
Ascierto PA; Capone M; Grimaldi AM; Mallardo D; Simeone E; Madonna G; Roder H; Meyer K; Asmellash S; Oliveira C; Roder J; Grigorieva J
J Immunother Cancer; 2019 Mar; 7(1):91. PubMed ID: 30925943
[TBL] [Abstract][Full Text] [Related]
8. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
Zhang L; Han X; Shi Y
JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB.
He J; Kalinava N; Doshi P; Pavlick DC; Albacker LA; Ebot EM; Tukachinsky H; Pratt J; Fusaro G; Oxnard GR; Green G; Fabrizio D; Baden J
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38035725
[TBL] [Abstract][Full Text] [Related]
10. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
11. Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden.
Florou V; Floudas CS; Maoz A; Naqash AR; Norton C; Tan AC; Sokol ES; Frampton G; Soares HP; Puri S; Swami U; Wilky B; Hosein P; Trent J; Lopes GL; Park W; Garrido-Laguna I
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586768
[TBL] [Abstract][Full Text] [Related]
12. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
13. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.
Forschner A; Battke F; Hadaschik D; Schulze M; Weißgraeber S; Han CT; Kopp M; Frick M; Klumpp B; Tietze N; Amaral T; Martus P; Sinnberg T; Eigentler T; Keim U; Garbe C; Döcker D; Biskup S
J Immunother Cancer; 2019 Jul; 7(1):180. PubMed ID: 31300034
[TBL] [Abstract][Full Text] [Related]
14. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
15. Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients.
Basak EA; van der Meer JWM; Hurkmans DP; Schreurs MWJ; Oomen-de Hoop E; van der Veldt AAM; Bins S; Joosse A; Koolen SLW; Debets R; Peeters RP; Aerts JGJV; Mathijssen RHJ; Medici M
Thyroid; 2020 Jul; 30(7):966-973. PubMed ID: 32151195
[No Abstract] [Full Text] [Related]
16. Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations.
DeLeon TT; Almquist DR; Kipp BR; Langlais BT; Mangold A; Winters JL; Kosiorek HE; Joseph RW; Dronca RS; Block MS; McWilliams RR; Kottschade LA; Rumilla KM; Voss JS; Seetharam M; Sekulic A; Markovic SN; Bryce AH
PLoS One; 2020; 15(3):e0230306. PubMed ID: 32196516
[TBL] [Abstract][Full Text] [Related]
17. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
18. Response to immune checkpoint inhibitor combination therapy in metastatic RET-mutated lung cancer from real-world retrospective data.
Yan N; Zhang H; Shen S; Guo S; Li X
BMC Cancer; 2024 Feb; 24(1):178. PubMed ID: 38317126
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
[TBL] [Abstract][Full Text] [Related]
20. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients.
Fässler M; Diem S; Mangana J; Hasan Ali O; Berner F; Bomze D; Ring S; Niederer R; Del Carmen Gil Cruz C; Pérez Shibayama CI; Krolik M; Siano M; Joerger M; Recher M; Risch L; Güsewell S; Risch M; Speiser DE; Ludewig B; Levesque MP; Dummer R; Flatz L
J Immunother Cancer; 2019 Feb; 7(1):50. PubMed ID: 30786924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
